Treatment With Zoledronate Subsequent to Denosumab in Osteoporosis: A 2-Year Randomized Study

Anne Sophie Sølling, Torben Harsløf, Bente Langdahl, Anne Sophie Sølling, Torben Harsløf, Bente Langdahl

Abstract

Increased bone turnover and rapid bone loss follow discontinuation of denosumab. We investigated the long-term efficacy of zoledronate (ZOL) in maintaining bone mineral density (BMD) after discontinuation of denosumab. In this randomized, open-label, interventional study, we included 61 postmenopausal women and men older than 50 years discontinuing denosumab after 4.6 ± 1.6 years. We administered ZOL 6 months (6 M) or 9 months (9 M) after the last denosumab or when bone turnover had increased (observation group [OBS]). ZOL was readministrated if p-cross-linked C-terminal telopeptide (p-CTX) increased ≥1.26 μg/L or BMD decreased ≥5%. The results after 12 months have previously been published; here we report the outcome after 24 months (ClinicalTrials NCT03087851). Fifty-eight patients completed the study. From 12 to 24 months after the initial ZOL, lumbar spine (LS) BMD was maintained: 0.9 ± 0.9%, 0.4 ± 0.8%, and 0.3 ± 0.7% in the 6 M, 9 M, and OBS groups, respectively (p > .05, no between-group differences). Similarly, total hip (TH) and femoral neck (FN) BMD did not change in any group during year 2. From baseline to 24 months after ZOL, LS BMD decreased by 4.0 ± 0.8%, 4.1 ± 0.8%, and 4.3 ± 1.5% in the 6 M, 9 M, and OBS groups, respectively (p < .001, no between-group differences). Significant bone loss (LS, TH, or FN) was found in all groups 24 months after ZOL: 6 M group: n = 12 (60%), 9 M group: n = 7 (37%), and OBS group: n = 10 (53%). P-CTX did not change significantly during the second year (p > .05, no between-group differences). No patient fulfilled the CTX or fracture criteria for retreatment during year 2; however, 9 patients were retreated at M24 due to BMD loss ≥5%. Two patients sustained a non-vertebral fracture during year 2. Treatment with ZOL subsequent to long-term denosumab did not fully prevent increased bone turnover and bone loss during the first year; however, CTX remained with the reference range and BMD was maintained during the second year. © 2021 American Society for Bone and Mineral Research (ASBMR).

Keywords: ANTIRESORPTIVES; BIOCHEMICAL MARKERS OF BONE TURNOVER; CLINICAL TRIAL; DXA; OSTEOPOROSIS.

© 2021 American Society for Bone and Mineral Research (ASBMR).

References

    1. Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of denosumab. Nat Rev Drug Discov. 2012;11(5):401-419.
    1. Miller PD, Bolognese MA, Lewiecki EM, et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222-229.
    1. Bone HG, Bolognese MA, Yuen CK, et al. Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab. 2011;96(4):972-980.
    1. Anastasilakis AD, Polyzos SA, Makras P, Aubry-Rozier B, Kaouri S, Lamy O. Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. J Bone Miner Res. 2017;32(6):1291-1296.
    1. Popp AW, Zysset PK, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab-from clinic and biomechanics. Osteoporos Int. 2016;27(5):1917-1921.
    1. Cummings SR, Ferrari S, Eastell R, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res. 2018;33(2):190-198.
    1. Sølling AS, Harsløf T, Langdahl B. Treatment with zoledronate subsequent to denosumab in osteoporosis: a randomized trial. J Bone Miner Res. 2020;35(10):1858-1870.
    1. Horne AM, Mihov B, Reid IR. Effect of zoledronate on bone loss after romosozumab/denosumab: 2-year follow-up. Calcif Tissue Int. 2019;105(1):107-108.
    1. Horne AM, Mihov B, Reid IR. Bone loss after romosozumab/denosumab: effects of bisphosphonates. Calcif Tissue Int. 2018;103(1):55-61.
    1. Zanchetta M, Pelegrin C, Silveira F, Salerni H, Zanchetta J. Bisphophonates prevent bone loss associated with denosumab treatment discontinuation. Presented at: ASBMR 2019 Annual Meeting; September 20-23, 2019; Orlando, FL. Abstract SAT-781.
    1. Fuller H, Fuller R, Pereira RMR. High resolution peripheral quantitative computed tomography for the assessment of morphological and mechanical bone parameters. Rev Bras Reumatol. 2015;55(4):352-362.
    1. Miller MA, Bare SP, Recker RR, Smith SY, Fox J. Intratrabecular tunneling increases trabecular number throughout the skeleton of ovariectomized rhesus monkeys treated with parathyroid hormone 1-84. Bone. 2008;42(6):1175-1183.
    1. McClung MR, Wagman RB, Miller PD, Wang A, Lewiecki EM. Observations following discontinuation of long-term denosumab therapy. Osteoporos Int. 2017;28(5):1723-1732.
    1. Popp AW, Varathan N, Buffat H, Senn C, Perrelet R, Lippuner K. Bone mineral density changes after 1 year of denosumab discontinuation in postmenopausal women with long-term denosumab treatment for osteoporosis. Calcif Tissue Int. 2018;103(1):50-54.
    1. Anastasilakis AD, Yavropoulou MP, Makras P, et al. Increased osteoclastogenesis in patients with vertebral fractures following discontinuation of denosumab treatment. Eur J Endocrinol. 2017;176(6):677-683.
    1. McDonald M, Khoo WH, Mohanty S, et al. Intravital imaging of osteoclasts in vivo reveals novel osteoclast fate which may underlie the therapeutic response to denosumab withdrawal. Presented at: ASBMR 2019 Annual Meeting; September 20-23, 2019; Orlando, FL. Abstract 1129.
    1. Fassio A, Adami G, Benini C, et al. Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. Bone. 2019;123:191-195.
    1. Fontalis A, Gossiel F, Schini M, Walsh J, Richard E. The effect of denosumab treatment on osteoclast precursor cells in postmenopausal osteoporosis. Presented at: ECTS 2020 Digital Congress; October 22-24, 2020. Poster 120.
    1. Ramchand S, David N, Hang L, Tsai JN, Leder B. Zoledronic acid maintains areal bone density after denosumab administration (DATA-HD extension). Presented at: ASBMR 2020 Annual Meeting Virtual Event; September 11-15, 2020. Abstract 1037.
    1. Ramchand S, David NL, Lee H, et al. Effect of zoledronic acid on volumetric bone density and microarchitecture after denosumab administration (DATA-HD extension HR-pQCT study). Presented at: ASBMR 2020 Annual Meeting Virtual Event; September 11-15, 2020. Abstract 1038.
    1. Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P. Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. A prospective 2-year clinical trial. J Bone Miner Res. 2019;34(12):2220-2228.
    1. Makras P, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Anastasilakis AD. The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Bone. 2020;138:115478.
    1. Anastasilakis AD, Polyzos SA, Yavropoulou MP, et al. Comparative effect of zoledronate at 6 versus 18 months following denosumab discontinuation. Calcif Tissue Int. Epub. 2021 Jan 2. Online ahead of print. .
    1. Lehmann T, Aeberli D. Possible protective effect of switching from denosumab to zoledronic acid on vertebral fractures. Osteoporos Int. 2017;28(10):3067-3068.
    1. Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T. A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Miner Res. 2020;35(7):1207-1215.
    1. Reid IR, Horne AM, Mihov B, Gamble GD. Bone loss after denosumab: only partial protection with zoledronate. Calcif Tissue Int. 2017;101(4):371-374.
    1. Tsourdi E, Zillikens MC, Meier C, et al. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020;756:dgaa756.
    1. Zebaze R, Ghasem-Zadeh A, Bohte A, et al. Intracortical remodelling and porosity in the distal radius and post-mortem femurs of women: a cross-sectional study. Lancet. 2010;375(9227):1729-1736.
    1. Tsai JN, Uihlein AV, Burnett-Bowie SM, et al. Effects of two years of teriparatide, denosumab, or both on bone microarchitecture and strength (DATA-HRpQCT study). J Clin Endocrinol Metab. 2016;101(5):2023-2030.
    1. Sikjaer T, Rejnmark L, Tietze A, Thomsen J, Brüel A, Mosekilde L. PTH (1-84) replacement therapy in hypoparathyroidism: effects on bone metabolism and structure. Presented at: IOF-ECCEO12 European Congress on Osteoporosis and Osteoarthritis; March 21-24, 2012; Bordeaux, France.
    1. Papapoulos S, Chapurlat R, Libanati C, et al. Five years of denosumab exposure in women with postmenopausal osteoporosis: results from the first two years of the FREEDOM extension. J Bone Miner Res. 2012;27(3):694-701.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi